Schizophrenia

New England Journal of Medicine

Volumn 349, Issue 18, 2003, Pages 1738-1749

  Freedman, Robert ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMPHETAMINE; ARIPIPRAZOLE; ATROPINE; BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; COCAINE; DOPAMINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LYSERGIDE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ANHEDONIA; BRADYKINESIA; BRAIN DYSFUNCTION; CATARACT; CHOREOATHETOSIS; CLINICAL FEATURE; COGNITION; DEATH; DELIRIUM; DIABETES MELLITUS; DOPAMINERGIC TRANSMISSION; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GENETIC EPIDEMIOLOGY; HALLUCINATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; LONG QT SYNDROME; MAINTENANCE THERAPY; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; PYRAMIDAL NERVE CELL; REVIEW; SALIVATION DISORDER; SCHIZOPHRENIA; SEIZURE; SUNBURN; TREMOR; VERTIGO; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CHILD; CLOZAPINE; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; PYRAMIDAL CELLS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 0142244688     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra035458     Document Type: Review

References (104)

1. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
2. Erlenmeyer-Kámling L. Early neurobehavioral deficits as phenotypic indicators of the schizophrenia genotype and predictors of later psychosis. Am J Med Genet 2001; 105:23-4.
3. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153: 321-30.
4. Swanson JW, Holzer CE M, Ganju VK, Jono RT. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hosp Community Psychiatry 1990;41:761-70. [Erratum, Hosp Community Psychiatry 1991;42:954-5.]
5. Swanson JW, Holzer CE M, Ganju VK, Jono RT. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hosp Community Psychiatry 1990;41:761-70. [Erratum, Hosp Community Psychiatry 1991;42:954-5.]
6. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001;15:127-35.
7. Berkeley G. A treatise concerning the principles of human knowledge. Dublin, Ireland: Jeremy Pepyat, 1710. (Also available at http://www.ilt.columbia.edu/publications/ digitext.html.)
8. Venables PH. Input dysfunction in schizophrenia. Prog Exp Personality Res 1964;1:1-47.
9. Park S, Holzman PS, Goldman-Rakic PS. Spatial worldng memory deficits in the relatives of schizophrenic patients. Arch Gen Psychiatry 1995;52:821-8.
10. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978;135:165-73.
11. Spohn HE, Lacousiere RB, Thompson K, Coyne L. Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Arch Gen Psychiatry 1977;34:633-44.
12. Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics: a textbook of pharmacology, toxicology, and therapeutics for physicians and medical students. 3rd ed. New York: Macmillan, 1965:165-6.
13. Pickar D, Labarca R, Doran AR, et al. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 1986;43:669-76.
14. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258-61.
15. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000;97:8104-9.
16. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000;287:2020-2.
17. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000;47:210-20.
18. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A 1998;95:5341-6.
19. Benes FM, Kwok EW, Vincent SL, TodtenkopfMS. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 1998;44: 88-97.
20. Akbarian S, Kim JJ, Potldn SG, Hetrick WP, Bunney WE Jr, Jones EG. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 1996;53:425-36.
21. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995;52:805-18.
22. Jeste DV, Lohr JB. Hippocampal pathologic findings in schizophrenia: a morphometric study. Arch Gen Psychiatry 1989;46: 1019-24.
23. Kubicki M, Shenton ME, Salisbury DF, et al. Voxel-based morphometric analysis of gray matter in first episode schizophrenia. Neuroimage 2002;17:1711-9.
24. Cecil KM, Lenkinski RE, Gur RE, Gur RC. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naïve patients with schizophrenia. Neuropsychopharmacology 1999;20:131-40.
25. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-30.
26. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-22.
27. McGuffin P, Riley B, Plomin R, Genomics and behavior: toward behavioral genomics. Science 2001;291:1232-49.
28. Chowdari KV, Mrinics K, Semwal P, et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002;11:1373-80.
29. Straub RE, Jiang Y, MacLean CJ, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002;71:337-48. [Errarum, Am J Hum Genet 2002;72:1007.]
30. Straub RE, Jiang Y, MacLean CJ, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002;71:337-48. [Errarum, Am J Hum Genet 2002;72:1007.]
31. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71:877-92.
32. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002;99:13675-80. [Erratum, Proc Natl Acad Sci U S A 2002;99:17221.]
33. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002;99:13675-80. [Erratum, Proc Natl Acad Sci U S A 2002;99:17221.]
34. Leonard S, Gault J, Hopkins J, et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002;59:1085-96.
35. Hoek HW, Brown AS, Susser E. The Dutch famine and schizophrenia spectrum disorders. Soc Psychiatry Psychiatr Epidemiol 1998;33:373-9.
36. Gearon JS, Kaltman SI, Brown C, Bellack AS. Traumatic life events and PTSD amongwomen with substance use disorders and schizophrenia. Psychiatr Serv 2003;54: 523-8.
37. Johnson SW, Palmer MR, Freedman R. Effects of dopamine on spontaneous and evoked activity of caudate neurons. Neuropharmacology 1983;22:843-51.
38. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 2000; 31:302-12.
39. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99: Suppl:S18-S27.
40. Hershman KM, Freedman R, Bickford PC. GABAB antagonists diminish the inhibitory gating of auditory response in the rathippocampus. Neurosci Lett 1995;190:133-6.
41. Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 2001;11:569-77.
42. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002;26:325-39.
43. Frazier CJ, Buhler AV, Weiner JL, Dunwiddie TV. Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci 1998;18:8228-35.
44. Madison DV, Nicoll RA. Norepinephrine decreases synaptic inhibition in the rat hippocampus. Brain Res 1988;442:131-8.
45. Herz MI, Marder SR. Schizophrenia: comprehensive treatment and management. Philadelphia: Lippincott Williams & Wilkins, 2002.
46. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3.
47. Nordstrom A, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral dose of haloperidol. Psychopharmacology (Berl) 1992;106:433-8.
48. Grace AA, Bunney BS. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharmacol Exp Ther 1986;238: 1092-100.
49. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 1974; 31:603-8.
50. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR, Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987;44:518-21.
51. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979;36:1283-94.
52. Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS. Typical antipsychotic drugs - D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002;56:31-6.
53. Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-51.
54. Cox B, Lee TF. Do central dopamine receptors have a physiological role in thermoregulation? Br J Pharmacol 1977;61:83-6.
55. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002;22;109-14.
56. Satanove A, McIntosh JS. Phototoxic reactions induced by high doses of chlorpromazine and thioridazine. JAMA 1967;200: 209-12.
57. Freedman R, Silverman MM, Schwab PJ. Patients' awareness of extrapyramidal reactions to neuroleptic drugs: possible evidence for the role of catecholamines in perception. Psychiatry Res 1979;1:31-8.
58. Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study. Hillside J Clin Psychiatry 1989; 11:107-19.
59. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994;151:836-41.
60. Suzuki A, Kondo T, Otani K, et al. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neurolepfic malignant syndrome. Am J Psychiatry 2001;158:1714-6.
61. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185-202.
62. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
63. Kapur S, McClelland RA, VanderSpek SC, et al. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport 2002;13:831-5.
64. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
65. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59:Suppl 3:3-7.
66. Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001;21: 382-8.
67. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf2002;25:91-110.
68. Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999;46:73-7.
69. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82-91.
70. Sernyak MJ, Desai R, Stolar M, Rosenheck R. Impact of clozapine on completed suicide. Am J Psychiatry 2001;158:931-7.
71. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999;46:125-9.
72. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-61.
73. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-57.
74. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
75. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505.
76. Csernansky JG, Mahmoud R, Brenner R, A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22. [Erratum, N Engl J Med 2002;346:1424.]
77. Csernansky JG, Mahmoud R, Brenner R, A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22. [Erratum, N Engl J Med 2002;346:1424.]
78. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002;28:5-16.
79. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001;58:965-72.
80. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1-A receptor. Eur J Pharmacol 2002;441:137-40.
81. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-90.
82. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
83. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62. [Erratum, Am J Psychiatry 2002;159:2132.]
84. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62. [Erratum, Am J Psychiatry 2002;159:2132.]
85. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
86. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.
87. de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry 2002;63:104-7.
88. Keefe KS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-22.
89. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
90. Cramer J, Rosenehck R, Xu W, Henderson W, Thomas J, Charney D. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr Bull 2001;27:227-34.
91. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002;51:972-8.
92. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154:Suppl:1-63.
93. Wyatt RJ, Henter ID. The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res 1998;32:169-77.
94. Buchanan RW, Breier A, Kirkpatrick B, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155:751-60.
95. Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome. Schizophr Bull 2002;28:63-73.
96. Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002;159:554-60.
97. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999;156:1138-48.
98. Biederman J, Lerner Y, Belmaker RH. Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. Arch Gen Psychiatry 1979;36: 327-33.
99. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991;148:714-26.
100. Comblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001;51: 31-8.
101. Schaeffer JL, Ross RG. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry 2002;41:538-45.
102. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921-8.
103. Gilmore JH, van Tol J, Kliewer MA, et al. Mild ventriculomegaly detected in utero with ultrasound: clinical associations and implications for schizophrenia. Schizophr Res 1998;33:133-40.
104. Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001;98:11650-5.